Zeljanz Blood Clot Injury Lawsuits: A Comprehensive Overview
FDA Raises Alarm on Zeljanz
In July 2019, the FDA issued a stark warning: the 10mg twice-daily dose of Xeljanz and Xeljanz XR (tofacitinib), primarily used for treating ulcerative colitis, carries an increased risk of blood clots and even death. This alarming update, delivered via the most serious “black box” warning, stemmed from data analysis of a safety trial involving rheumatoid arthritis patients.
For deeper information on the FDA’s Zeljanz drug safety notice:
- Read the full Zeljanz FDA communication: Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication – Due to an Increased Risk of Blood Clots and Death with Higher Dose.
Zeljanz Restrictions and Concerns
The use of tofacitinib for ulcerative colitis is now tightly restricted, applying only to specific patient profiles. Notably, the safety trial compared both a lower and the higher (now restricted) dose, highlighting the dose-dependent nature of the increased risk.
Zeljanz Patient Impact and Legal Implications
Individuals using Zeljanz, particularly those on the higher dose for ulcerative colitis, have reported experiencing severe blood clot-related injuries. These reports have spurred legal action to address such complications.
Seeking Legal Recourse For Zeljanz Injuries
If you or a loved one has suffered blood clot-related complications or death after using Zeljanz, The Levensten Law Firm, P.C., stands ready to help. We offer legal consultations and representation, committed to protecting your rights and exploring potential compensation through a Zeljanz claim.
Contact The Levensten Law Firm, P.C.
At The Levensten Law Firm, P.C., we are dedicated to supporting individuals affected by the adverse effects of Zeljanz. If you have questions or want to learn more about your legal rights and the claim filing process, please don’t hesitate to contact us.
